PAVmed secures $2.4m to advance Veris Health’s implantable cancer monitoring technology

PAVmed Inc., a diversified commercial-stage medical technology company, has completed a $2.37 million private placement financing, reinforcing its investment in Veris Health Inc., a majority-owned subsidiary focused on advanced remote patient monitoring solutions for cancer care. The financing, conducted at at-the-market pricing, assigns Veris Health a pre-money valuation of approximately $35 million.

The proceeds will accelerate the regulatory and commercial development of Veris Health’s implantable physiological monitor, a device designed to transform cancer patient management through continuous physiological data collection. The funding also supplements a recent $1.8 million non-dilutive NIH grant, further strengthening Veris Health’s expansion into the rapidly evolving digital health and oncology technology market.

Transforming Cancer Care with Remote Patient Monitoring

The increasing demand for personalized cancer care solutions has fueled investments in digital health technologies that facilitate early detection of complications, improved patient monitoring, and data-driven decision-making. Veris Health’s proprietary cancer care platform integrates implantable biologic sensors with a connected suite of external monitoring devices, enabling healthcare providers to track real-time physiological data remotely.

The implantable physiological monitor is designed to be inserted alongside a vascular access port, a common component in chemotherapy treatments. By collecting continuous physiological data without relying on patient compliance, this device offers a comprehensive, real-time assessment of a patient’s health status. The platform aims to reduce unplanned hospitalizations, enhance clinical decision-making, and improve patient outcomes.

Industry experts suggest that integrating real-time physiological data into oncology care could significantly improve treatment outcomes by allowing for earlier intervention in case of complications. This technology aligns with broader industry trends emphasizing preventative care, personalized treatment strategies, and the reduction of healthcare costs associated with emergency interventions.

Funding to Drive Market Expansion and Regulatory Approvals

The cancer care platform is currently undergoing regulatory review, with Veris Health targeting FDA clearance and a commercial launch in the near future. The newly secured funding will support clinical validation studies, regulatory submissions, and initial market penetration efforts.

Healthcare technology analysts highlight that the ability to remotely monitor cancer patients using implantable physiological sensors represents a critical advancement in oncology care management. As the digital health sector continues to grow, companies specializing in remote patient monitoring solutions are attracting increased investor interest.

This latest private placement financing is expected to accelerate Veris Health’s market readiness, positioning the company as a key player in the digital health ecosystem. With the demand for connected healthcare solutions expanding, Veris Health’s innovative approach to cancer patient monitoring could set a new standard for data-driven oncology treatment.

PAVmed Expands Digital Health Portfolio with Veris Health and Lucid Diagnostics

PAVmed’s investment in Veris Health is part of its broader digital health and medical technology strategy, which includes Lucid Diagnostics, a commercial-stage medical diagnostics company specializing in esophageal cancer prevention. Lucid markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, which provide the first and only commercially available tools for early detection of esophageal precancer.

By expanding its portfolio to include oncology-focused remote patient monitoring, PAVmed is positioning itself at the forefront of digital transformation in healthcare. The convergence of biologic sensors, cloud-based analytics, and patient-centric care models is shaping the future of precision medicine.

Industry analysts note that digital health companies offering innovative, compliance-independent monitoring solutions are expected to see strong adoption across healthcare systems. As regulatory approvals progress, the potential for scalable deployment in cancer centers and oncology networks remains a key driver of long-term commercial success.

The Future of Digital Oncology Care

The global oncology technology landscape is evolving rapidly, with digital health innovations enabling greater personalization, real-time data collection, and enhanced clinical decision-making. Veris Health’s cancer care platform represents a step toward integrating real-world patient data into oncology treatment plans, reducing complications, and improving long-term survival rates.

With regulatory approvals on the horizon and continued investor confidence, PAVmed and Veris Health are well-positioned to reshape cancer patient monitoring through advanced digital health solutions.